[en] Recent studies have highlighted the biological significance of exosomes and m6A modifications in immunity. Nonetheless, it remains unclear whether the m6A modification gene in exosomes of body fluid has potential roles in the tumor microenvironment (TME). Herein, we identified three different m6A-related exosomal gene modification patterns based on 59 m6A-related exosomal genes, which instructed distinguishing characteristics of TME in colon cancer (CC). We demonstrated that these patterns could predict the stage of tumor inflammation, subtypes, genetic variation, and patient prognosis. Furthermore, we developed a scoring mode-m6A-related exosomal gene score (MREGS)-by detecting the level of m6A modification in exosomes to classify immune phenotypes. Low MREGS, characterized by prominent survival and immune activation, was linked to a better response to anti-PDL1 immunotherapy. In contrast, the higher MREGS group displayed remarkable stromal activation, high activity of innate immunocytes, and a lower survival rate. Hence, this work provides a novel approach for evaluating TME cell infiltration in colon cancer and guiding more effective immunotherapy strategies.
Disciplines :
Immunology & infectious disease
Author, co-author :
Zheng, Junjie; Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
Feng, Panpan; Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China ; Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
Chen, Dawei ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Zhang, Cuiyu; Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
Ji, Yuge; State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361101, China
Liu, Yanting; Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
Fan, Xiaohua ; Department of Rehabilitation Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China
Li, Jingxin ; Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
Language :
English
Title :
m6A Regulator-Based Exosomal Gene Methylation Modification Patterns Identify Distinct Microenvironment Characterization and Predict Immunotherapeutic Responses in Colon Cancer.
Boccaletto P., Machnicka M. A., Purta E., Piątkowski P., Bagiński B., Wirecki T. K., de Crécy-Lagard V., Ross R., Limbach P. A., Kotter A., Helm M., Bujnicki J. M., MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Research 2018, 46, D1, D303, D307, 10.1093/nar/gkx1030, 2-s2.0-85040867824, 29106616
Liu Z. X., Li L. M., Sun H. L., Liu S. M., Link between m6A modification and cancers. Frontiers in Bioengineering and Biotechnology 2018, 6, 89, 10.3389/fbioe.2018.00089, 30062093,
Yang Y., Hsu P. J., Chen Y.-S., Yang Y.-G., Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Research 2018, 28, 6, 616, 624, 10.1038/s41422-018-0040-8, 2-s2.0-85047246590, 29789545,
Chen X.-Y., Wang D., Peng H., Chen X., Han X., Yu J., Wang W., Liang L., Liu Z., Zheng Y., Hu J., Yang L., Li J., Zhou H., Cui X., Li F., Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLC ϵ-NF-κ B signaling pathway and VEGF-C/ Bcl-2 expression. Molecular Cancer 2019, 18, 1, 1, 10.1186/s12943-018-0930-x, 2-s2.0-85059500088, 30609930
Yang Q., Xu F., Jian A., Yu H., Ye T., Hu W., m6A regulator-mediated methylation modification patterns and tumor microenvironment cell-infiltration characterization in head and neck cancer. Frontiers in Cell and Developmental Biology 2021, 9, 803141, 10.3389/fcell.2021.803141,
Zhang B., Wu Q., Li B., Wang D., Wang L., Zhou Y. L., m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Molecular Cancer 2020, 19, 1, 53, 10.1186/s12943-020-01170-0, 32164750,
Hou J., Shan H., Zhang Y., Fan Y., Wu B., m6A RNA methylation regulators have prognostic value in papillary thyroid carcinoma. American Journal of Otolaryngology 2020, 41, 4, article 102547, 10.1016/j.amjoto.2020.102547, 32474328,
Pan B., Johnstone R., Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33, 3, 967, 978, 10.1016/0092-8674(83)90040-5, 2-s2.0-0020956787, 6307529
He L., Li H., Wu A., Peng Y., Shu G., Yin G., Functions of N6-methyladenosine and its role in cancer. Molecular Cancer 2019, 18, 1, 176, 10.1186/s12943-019-1109-9, 31801551
Quail D. F., Joyce J. A., Microenvironmental regulation of tumor progression and metastasis. Nature Medicine 2013, 19, 11, 1423, 1437, 10.1038/nm.3394, 2-s2.0-84887444879, 24202395
Ge Y., Mu W., Ba Q., Li J., Jiang Y., Xia Q., Wang H., Hepatocellular carcinoma-derived exosomes in organotropic metastasis, recurrence and early diagnosis application. Cancer Letters 2020, 477, 41, 48, 10.1016/j.canlet.2020.02.003, 32112905
Li X., Li C., Zhang L., Wu M., Cao K., Jiang F., Chen D., Li N., Li W., The significance of exosomes in the development and treatment of hepatocellular carcinoma. Molecular Cancer 2020, 19, 1, 1, 11, 10.1186/s12943-019-1085-0, 31901224
Schmoll H., van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Nordlinger B., van de Velde C. J., Balmana J., Regula J., Nagtegaal I. D., Beets-Tan R. G., Arnold D., Ciardiello F., Hoff P., Kerr D., Köhne C. H., Labianca R., Price T., Scheithauer W., Sobrero A., Tabernero J., Aderka D., Barroso S., Bodoky G., Douillard J. Y., el Ghazaly H., Gallardo J., Garin A., Glynne-Jones R., Jordan K., Meshcheryakov A., Papamichail D., Pfeiffer P., Souglakos I., Turhal S., Cervantes A., ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology 2012, 23, 10, 2479, 2516, 10.1093/annonc/mds236, 2-s2.0-84867122727, 23012255
Siegel R. L., Miller K. D., Fedewa S. A., Ahnen D. J., Meester R. G. S., Barzi A., Jemal A., Colorectal cancer statistics, 2017. CA: a Cancer Journal for Clinicians 2017, 67, 3, 177, 193, 10.3322/caac.21395, 2-s2.0-85014032221
Le D. T., Durham J. N., Smith K. N., Wang H., Bartlett B. R., Aulakh L. K., Lu S., Kemberling H., Wilt C., Luber B. S., Wong F., Azad N. S., Rucki A. A., Laheru D., Donehower R., Zaheer A., Fisher G. A., Crocenzi T. S., Lee J. J., Greten T. F., Duffy A. G., Ciombor K. K., Eyring A. D., Lam B. H., Joe A., Kang S. P., Holdhoff M., Danilova L., Cope L., Meyer C., Zhou S., Goldberg R. M., Armstrong D. K., Bever K. M., Fader A. N., Taube J., Housseau F., Spetzler D., Xiao N., Pardoll D. M., Papadopoulos N., Kinzler K. W., Eshleman J. R., Vogelstein B., Anders R. A., Diaz L. A., Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017, 357, 6349, 409, 413, 10.1126/science.aan6733, 2-s2.0-85026265866, 28596308
Xiao Y., Freeman G. J., The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discovery 2015, 5, 1, 16, 18, 10.1158/2159-8290.CD-14-1397, 2-s2.0-84922367332, 25583798
Binnewies M., Roberts E. W., Kersten K., Chan V., Fearon D. F., Merad M., Coussens L. M., Gabrilovich D. I., Ostrand-Rosenberg S., Hedrick C. C., Vonderheide R. H., Pittet M. J., Jain R. K., Zou W., Howcroft T. K., Woodhouse E. C., Weinberg R. A., Krummel M. F., Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine 2018, 24, 5, 541, 550, 10.1038/s41591-018-0014-x, 2-s2.0-85045833745, 29686425
Li X., Wen D., Li X., Yao C., Chong W., Chen H., Identification of an immune signature predicting prognosis risk and lymphocyte infiltration in colon cancer. Frontiers in Immunology 2020, 11, 1678, 10.3389/fimmu.2020.01678, 33013820
Wilkerson M. D., Hayes D. N., ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26, 12, 1572, 1573, 10.1093/bioinformatics/btq170, 2-s2.0-77954182362, 20427518
Shao X., Lv N., Liao J., Long J., Xue R., Ai N., Xu D., Fan X., Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Medical Genetics 2019, 20, 1, 175, 10.1186/s12881-019-0909-5, 31706287
Martincorena I., Campbell P. J., Somatic mutation in cancer and normal cells. Science 2015, 349, 6255, 1483, 1489, 10.1126/science.aab4082, 2-s2.0-84942236803
Chen D. S., Mellman I., Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 7637, 321, 330, 10.1038/nature21349, 2-s2.0-85016548232, 28102259
Marisa L., de Reyniès A., Duval A., Selves J., Gaub M. P., Vescovo L., Etienne-Grimaldi M.-C., Schiappa R., Guenot D., Ayadi M., Kirzin S., Chazal M., Fléjou J.-F., Benchimol D., Berger A., Lagarde A., Pencreach E., Piard F., Elias D., Parc Y., Olschwang S., Milano G., Laurent-Puig P., Boige V., Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Medicine 2013, 10, 5, article e1001453, 10.1371/journal.pmed.1001453, 2-s2.0-84878302099, 23700391
Barbie D. A., Tamayo P., Boehm J. S., Kim S. Y., Moody S. E., Dunn I. F., Schinzel A. C., Sandy P., Meylan E., Scholl C., Fröhling S., Chan E. M., Sos M. L., Michel K., Mermel C., Silver S. J., Weir B. A., Reiling J. H., Sheng Q., Gupta P. B., Wadlow R. C., le H., Hoersch S., Wittner B. S., Ramaswamy S., Livingston D. M., Sabatini D. M., Meyerson M., Thomas R. K., Lander E. S., Mesirov J. P., Root D. E., Gilliland D. G., Jacks T., Hahn W. C., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462, 7269, 108, 112, 10.1038/nature08460, 2-s2.0-70449091786, 19847166
Zeng D., Li M., Zhou R., Zhang J., Sun H., Shi M., Bin J., Liao Y., Rao J., Liao W., Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunology Research 2019, 7, 5, 737, 750, 10.1158/2326-6066.CIR-18-0436, 2-s2.0-85065508481, 30842092
Kalluri R., The biology and function of fibroblasts in cancer. Nature Reviews. Cancer 2016, 16, 9, 582, 598, 10.1038/nrc.2016.73, 2-s2.0-84984694266
Calon A., Espinet E., Palomo-Ponce S., Tauriello D. V. F., Iglesias M., Céspedes M. V., Sevillano M., Nadal C., Jung P., Zhang X. H. F., Byrom D., Riera A., Rossell D., Mangues R., Massagué J., Sancho E., Batlle E., Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22, 5, 571, 584, 10.1016/j.ccr.2012.08.013, 2-s2.0-84869021181, 23153532
Ganesh K., Stadler Z. K., Cercek A., Mendelsohn R. B., Shia J., Segal N. H., Diaz L. A. Jr., Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Reviews. Gastroenterology & Hepatology 2019, 16, 6, 361, 375, 10.1038/s41575-019-0126-x, 2-s2.0-85064931629, 30886395
Samstein R. M., Lee C. H., Shoushtari A. N., Hellmann M. D., Shen R., Janjigian Y. Y., Barron D. A., Zehir A., Jordan E. J., Omuro A., Kaley T. J., Kendall S. M., Motzer R. J., Hakimi A. A., Voss M. H., Russo P., Rosenberg J., Iyer G., Bochner B. H., Bajorin D. F., al-Ahmadie H. A., Chaft J. E., Rudin C. M., Riely G. J., Baxi S., Ho A. L., Wong R. J., Pfister D. G., Wolchok J. D., Barker C. A., Gutin P. H., Brennan C. W., Tabar V., Mellinghoff I. K., DeAngelis L. M., Ariyan C. E., Lee N., Tap W. D., Gounder M. M., D'Angelo S. P., Saltz L., Stadler Z. K., Scher H. I., Baselga J., Razavi P., Klebanoff C. A., Yaeger R., Segal N. H., Ku G. Y., DeMatteo R. P., Ladanyi M., Rizvi N. A., Berger M. F., Riaz N., Solit D. B., Chan T. A., Morris L. G. T., Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics 2019, 51, 2, 202, 206, 10.1038/s41588-018-0312-8, 2-s2.0-85059965982, 30643254
Schumacher T. N., Schreiber R. D., Neoantigens in cancer immunotherapy. Science 2015, 348, 6230, 69, 74, 10.1126/science.aaa4971, 2-s2.0-84928770388
Milane L., Singh A., Mattheolabakis G., Suresh M., Amiji M. M., Exosome mediated communication within the tumor microenvironment. Journal of Controlled Release 2015, 219, 278, 294, 10.1016/j.jconrel.2015.06.029, 2-s2.0-85047700200
Ruivo C. F., Adem B., Silva M., Melo S. A., The biology of cancer exosomes: insights and new perspectives. Cancer Research 2017, 77, 23, 6480, 6488, 10.1158/0008-5472.CAN-17-0994, 2-s2.0-85038637162, 29162616
Turley S. J., Cremasco V., Astarita J. L., Immunological hallmarks of stromal cells in the tumour microenvironment. Nature Reviews. Immunology 2015, 15, 11, 669, 682, 10.1038/nri3902, 2-s2.0-84945451852, 26471778
Gajewski T. F., Woo S. R., Zha Y., Spaapen R., Zheng Y., Corrales L., Spranger S., Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Current Opinion in Immunology 2013, 25, 2, 268, 276, 10.1016/j.coi.2013.02.009, 2-s2.0-84877072174, 23579075
Gajewski T. F., The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Seminars in Oncology 2015, 42, 4, 663, 671, 10.1053/j.seminoncol.2015.05.011, 2-s2.0-84940372582, 26320069
Joyce J. A., Fearon D. T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348, 6230, 74, 80, 10.1126/science.aaa6204, 2-s2.0-84928896256, 25838376
Salmon H., Franciszkiewicz K., Damotte D., Dieu-Nosjean M. C., Validire P., Trautmann A., Mami-Chouaib F., Donnadieu E., Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. The Journal of Clinical Investigation 2012, 122, 3, 899, 910, 10.1172/JCI45817, 2-s2.0-84857826513, 22293174
Tauriello D. V. F., Palomo-Ponce S., Stork D., Berenguer-Llergo A., Badia-Ramentol J., Iglesias M., Sevillano M., Ibiza S., Cañellas A., Hernando-Momblona X., Byrom D., Matarin J. A., Calon A., Rivas E. I., Nebreda A. R., Riera A., Attolini C. S. O., Batlle E., TGF β drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018, 554, 7693, 538, 543, 10.1038/nature25492, 2-s2.0-85042540245, 29443964
Mariathasan S., Turley S. J., Nickles D., Castiglioni A., Yuen K., Wang Y., Kadel III E. E., Koeppen H., Astarita J. L., Cubas R., Jhunjhunwala S., Banchereau R., Yang Y., Guan Y., Chalouni C., Ziai J., Şenbabaoǧlu Y., Santoro S., Sheinson D., Hung J., Giltnane J. M., Pierce A. A., Mesh K., Lianoglou S., Riegler J., Carano R. A. D., Eriksson P., Höglund M., Somarriba L., Halligan D. L., van der Heijden M. S., Loriot Y., Rosenberg J. E., Fong L., Mellman I., Chen D. S., Green M., Derleth C., Fine G. D., Hegde P. S., Bourgon R., Powles T., TGF β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018, 554, 7693, 544, 548, 10.1038/nature25501, 2-s2.0-85042495633, 29443960
Panagi M., Voutouri C., Mpekris F., Papageorgis P., Martin M. R., Martin J. D., Demetriou P., Pierides C., Polydorou C., Stylianou A., Louca M., Koumas L., Costeas P., Kataoka K., Cabral H., Stylianopoulos T., TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics 2020, 10, 4, 1910, 1922, 10.7150/thno.36936, 32042344
Chalmers Z. R., Connelly C. F., Fabrizio D., Gay L., Ali S. M., Ennis R., Schrock A., Campbell B., Shlien A., Chmielecki J., Huang F., He Y., Sun J., Tabori U., Kennedy M., Lieber D. S., Roels S., White J., Otto G. A., Ross J. S., Garraway L., Miller V. A., Stephens P. J., Frampton G. M., Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine 2017, 9, 1, 34, 10.1186/s13073-017-0424-2, 2-s2.0-85018500416, 28420421
Le D. T., Uram J. N., Wang H., Bartlett B. R., Kemberling H., Eyring A. D., Skora A. D., Luber B. S., Azad N. S., Laheru D., Biedrzycki B., Donehower R. C., Zaheer A., Fisher G. A., Crocenzi T. S., Lee J. J., Duffy S. M., Goldberg R. M., de la Chapelle A., Koshiji M., Bhaijee F., Huebner T., Hruban R. H., Wood L. D., Cuka N., Pardoll D. M., Papadopoulos N., Kinzler K. W., Zhou S., Cornish T. C., Taube J. M., Anders R. A., Eshleman J. R., Vogelstein B., Diaz L. A., PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine 2015, 372, 26, 2509, 2520, 10.1056/NEJMoa1500596, 2-s2.0-84932628341, 26028255
Anagnostou V., Smith K. N., Forde P. M., Niknafs N., Bhattacharya R., White J., Zhang T., Adleff V., Phallen J., Wali N., Hruban C., Guthrie V. B., Rodgers K., Naidoo J., Kang H., Sharfman W., Georgiades C., Verde F., Illei P., Li Q. K., Gabrielson E., Brock M. V., Zahnow C. A., Baylin S. B., Scharpf R. B., Brahmer J. R., Karchin R., Pardoll D. M., Velculescu V. E., Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discovery 2017, 7, 3, 264, 276, 10.1158/2159-8290.CD-16-0828, 2-s2.0-85014747024, 28031159
Wang Y., Shi J., Chai K., Ying X., Zhou B., The role of snail in EMT and tumorigenesis. Current Cancer Drug Targets 2013, 13, 9, 963, 972, 10.2174/15680096113136660102, 2-s2.0-84890852964, 24168186
Auclin E., Zaanan A., Vernerey D., Douard R., Gallois C., Laurent-Puig P., Bonnetain F., Taieb J., Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Annals of Oncology 2017, 28, 5, 958, 968, 10.1093/annonc/mdx030, 2-s2.0-85042641942, 28453690
Zheng J., Chen D., Zhang C., Ji Y., Liu Y., Fan X., Li J., m6A related exosome gene siganture in colon cancer identifies distinct microenvironment characterization and immunotherapeutical responses. 10.21203/rs.3.rs-895661/v1,
